The above observations suggested that ALA may reduce inflammatory cytokine secretion by inhibiting hepatic NLRP3 inflammasome activation, suppressing IR and lipid accumulation in the liver, and, subsequently, alleviating the occurrence of NAFLD in T2DM. Here, NLRP3 is linked to metabolic dysfunction-associated steatotic liver disease.